Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444589 | 0.86 | KMT2A (0.43) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL6050843 | 0.86 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL5437609 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL5435686 | 0.83 | XDH (0.45) | KDM4EALDH1A1HTTNPSR1HPGD | |
| SCHEMBL5434638 | 0.82 | MEN1 (0.47) | KDM4EALDH1A1MAPTMAPK1USP2 | |
| SCHEMBL5434556 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL5454885 | 0.80 | BRDT (0.44) | KDM4EALDH1A1SMN1; SMN2TP53TSHR | |
| SCHEMBL5434692 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL5437075 | 0.77 | KDM4E (0.41) | KDM4EALDH1A1MAPTLMNAHPGD | |
| SCHEMBL5435678 | 0.75 | KDM4E (0.42) | PDE4APDE4BPDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-02-22 | — | — | US | claimed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | claimed |
| US-6946465-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2005-09-20 | — | — | US | claimed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | claimed |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2003-12-25 | — | — | US | claimed |
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-02-22 | — | — | US | disclosed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | disclosed |
| US-6946465-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2005-09-20 | — | — | US | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | PDE4A 3117/4885PDE4B 3799/4885PDE4C 3161/4885 |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | PDE4A 2989/4885PDE4B 3683/4885PDE4C 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.